Artiva Biotherapeutics Inc. (ARTV) Insider Trading

Last 12 months

Insiders bought $7.38M and sold $2.52M on the open market.

23% of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

+$4.86M

3 buys · 19 sales

Under a 10b5-1 plan

23%

of the value sold

Insiders who bought / sold

2 / 5

executives and directors

Last open-market buy

Jul 2026

Jul 23, 2026

Get an email when ARTV's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 6	Fred Aslan Chief Executive Officer	Sold10b5-1 plan	23,463	$7.20	$169k	1.5%	Form 4
Oct 5	Christopher Horan Chief Tech Operations Officer	SoldNo plan	10,340	$6.84	$71k	3.2%	Form 4
Oct 5	Jennifer Bush COO, CLO, Compliance Officer	SoldNo plan	8,370	$6.84	$57k	2.2%	Form 4
Oct 5	Subhashis Banerjee Chief Medical Officer	SoldNo plan	1,099	$6.84	$8k	0.6%	Form 4
Oct 5	Fred Aslan Chief Executive Officer	SoldNo plan	61,696	$6.84	$422k	3.8%	Form 4
Sep 8	Fred Aslan Chief Executive Officer	Sold10b5-1 plan	23,429	$10.92	$256k	1.6%	Form 4
Sep 3	Christopher Horan Chief Tech Operations Officer	SoldNo plan	10,366	$11.16	$116k	3.5%	Form 4
Sep 3	Jennifer Bush COO, CLO, Compliance Officer	SoldNo plan	8,391	$11.16	$94k	2.5%	Form 4
Sep 3	Subhashis Banerjee Chief Medical Officer	SoldNo plan	1,100	$11.16	$12k	0.8%	Form 4
Sep 3	Fred Aslan Chief Executive Officer	SoldNo plan	61,888	$11.16	$691k	4.0%	Form 4
Aug 27	Subhashis Banerjee Chief Medical Officer	Sold10b5-1 plan	8,222	$12.01	$99k	5.5%	Form 4
Aug 18	Subhashis Banerjee Chief Medical Officer	Sold10b5-1 plan	429	$12.00	$5k	0.3%	Form 4
Jul 29 – 31	RA Capital Healthcare Fund LP Large holder	Bought 2 parts	45,768	$9.96 average	$456k	0.3%	Form 4
Jul 24	RA Capital Nexus Fund Iii, L.p. Large holder	Bought	41,319	$9.99	$413k	0.2%	Form 4
Jul 21 – 23	Peter Kolchinsky Director	Bought 3 parts	264,586	$9.76 average	$2.58M	1.6%	Form 4
Jul 16 – 17	RA Capital Healthcare Fund LP Large holder	Bought 2 parts	160,354	$8.93 average	$1.43M	1.0%	Form 4
Jul 13	RA Capital Nexus Fund, L.p. Large holder	Bought	6,522	$8.94	$58k	<0.1%	Form 4
Jul 10 – 13	Rajeev M. Shah Director	Bought 2 parts	21,654	$8.96 average	$194k	0.1%	Form 4
Jun 25 – 26	RA Capital Management, L.p. Large holder	Bought 2 parts	32,876	$8.89 average	$292k	0.2%	Form 4
Jun 12 – 16	Peter Kolchinsky Director	Bought 3 parts	531,326	$8.66 average	$4.6M	3.3%	Form 4
Jun 9 – 11	RA Capital Nexus Fund, L.p. Large holder	Bought 3 parts	1,027,722	$7.44 average	$7.65M	6.8%	Form 4
May 19	Heather Raymon SVP, Research and Development	SoldNo plan	3,095	$9.01	$28k	2.0%	Form 4
May 19	Christopher Horan Chief Tech Operations Officer	SoldNo plan	7,002	$9.01	$63k	2.3%	Form 4
May 19	Jennifer Bush COO, CLO, Compliance Officer	SoldNo plan	8,790	$9.01	$79k	2.5%	Form 4
May 19	Subhashis Banerjee Chief Medical Officer	SoldNo plan	7,037	$9.01	$63k	4.6%	Form 4
May 19	Fred Aslan Chief Executive Officer	SoldNo plan	27,116	$9.01	$244k	1.7%	Form 4
May 11	GC Corp. Large holder	Bought 2 parts	1,432,291	$11.52 average	$16.5M	31%	Form 4
May 11	RA Capital Nexus Fund Iii, L.p. Large holder	Bought	6,510,416	$11.52	$75M	75%	Form 4
Dec 15, 2025	Fred Aslan President and CEO	Sold10b5-1 plan	3,187	$6.00	$19k	0.3%	Form 4
Nov 17, 2025	Fred Aslan President and CEO	Sold10b5-1 plan	6,375	$3.38	$22k	1.8%	Form 4
Oct 17, 2025	Fred Aslan President and CEO	Sold10b5-1 plan	25,500	$6.00	$153k	6.7%	Form 4
Aug 15, 2025	Fred Aslan President and CEO	Sold10b5-1 plan	25,500	$2.73	$70k	6.3%	Form 4

Oct 610b5-1 plan
Fred Aslan
Chief Executive Officer · sold 23,463 at $7.20
$169k
1.5% of stake
Oct 5No plan
Christopher Horan
Chief Tech Operations Officer · sold 10,340 at $6.84
$71k
3.2% of stake
Oct 5No plan
Jennifer Bush
COO, CLO, Compliance Officer · sold 8,370 at $6.84
$57k
2.2% of stake
Oct 5No plan
Subhashis Banerjee
Chief Medical Officer · sold 1,099 at $6.84
$8k
0.6% of stake
Oct 5No plan
Fred Aslan
Chief Executive Officer · sold 61,696 at $6.84
$422k
3.8% of stake
Sep 810b5-1 plan
Fred Aslan
Chief Executive Officer · sold 23,429 at $10.92
$256k
1.6% of stake
Sep 3No plan
Christopher Horan
Chief Tech Operations Officer · sold 10,366 at $11.16
$116k
3.5% of stake
Sep 3No plan
Jennifer Bush
COO, CLO, Compliance Officer · sold 8,391 at $11.16
$94k
2.5% of stake
Sep 3No plan
Subhashis Banerjee
Chief Medical Officer · sold 1,100 at $11.16
$12k
0.8% of stake
Sep 3No plan
Fred Aslan
Chief Executive Officer · sold 61,888 at $11.16
$691k
4.0% of stake
Aug 2710b5-1 plan
Subhashis Banerjee
Chief Medical Officer · sold 8,222 at $12.01
$99k
5.5% of stake
Aug 1810b5-1 plan
Subhashis Banerjee
Chief Medical Officer · sold 429 at $12.00
$5k
0.3% of stake
Jul 29 – 31
RA Capital Healthcare Fund LP
Large holder · bought 45,768 at avg $9.96
$456k
0.3% of stake
Jul 24
RA Capital Nexus Fund Iii, L.p.
Large holder · bought 41,319 at $9.99
$413k
0.2% of stake
Jul 21 – 23
Peter Kolchinsky
Director · bought 264,586 at avg $9.76
$2.58M
1.6% of stake
Jul 16 – 17
RA Capital Healthcare Fund LP
Large holder · bought 160,354 at avg $8.93
$1.43M
1.0% of stake
Jul 13
RA Capital Nexus Fund, L.p.
Large holder · bought 6,522 at $8.94
$58k
<0.1% of stake
Jul 10 – 13
Rajeev M. Shah
Director · bought 21,654 at avg $8.96
$194k
0.1% of stake
Jun 25 – 26
RA Capital Management, L.p.
Large holder · bought 32,876 at avg $8.89
$292k
0.2% of stake
Jun 12 – 16
Peter Kolchinsky
Director · bought 531,326 at avg $8.66
$4.6M
3.3% of stake
Jun 9 – 11
RA Capital Nexus Fund, L.p.
Large holder · bought 1,027,722 at avg $7.44
$7.65M
6.8% of stake
May 19No plan
Heather Raymon
SVP, Research and Development · sold 3,095 at $9.01
$28k
2.0% of stake
May 19No plan
Christopher Horan
Chief Tech Operations Officer · sold 7,002 at $9.01
$63k
2.3% of stake
May 19No plan
Jennifer Bush
COO, CLO, Compliance Officer · sold 8,790 at $9.01
$79k
2.5% of stake
May 19No plan
Subhashis Banerjee
Chief Medical Officer · sold 7,037 at $9.01
$63k
4.6% of stake
May 19No plan
Fred Aslan
Chief Executive Officer · sold 27,116 at $9.01
$244k
1.7% of stake
May 11
GC Corp.
Large holder · bought 1,432,291 at avg $11.52
$16.5M
31% of stake
May 11
RA Capital Nexus Fund Iii, L.p.
Large holder · bought 6,510,416 at $11.52
$75M
75% of stake
Dec 15, 202510b5-1 plan
Fred Aslan
President and CEO · sold 3,187 at $6.00
$19k
0.3% of stake
Nov 17, 202510b5-1 plan
Fred Aslan
President and CEO · sold 6,375 at $3.38
$22k
1.8% of stake
Oct 17, 202510b5-1 plan
Fred Aslan
President and CEO · sold 25,500 at $6.00
$153k
6.7% of stake
Aug 15, 202510b5-1 plan
Fred Aslan
President and CEO · sold 25,500 at $2.73
$70k
6.3% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ARTV, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

GLUEMonte Rosa Therapeutics, Inc.

ALGSAligos Therapeutics Inc.

SRRKScholar Rock Holding Corporation

ALECAlector Inc.

XFORX4 Pharmaceuticals Inc.

TARSTarsus Pharmaceuticals Inc.

AMGNAmgen Inc.

CHRSCoherus Biosciences Inc.

Spot a number that looks wrong? Check it in ARTV's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ARTV

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.